CorVel Corporation — Form 10-Q Summary
Period: Three months ended June 30, 2017, the first quarter of CorVel’s fiscal 2018; filed August 4, 2017. The request metadata says “2016 Q1,” but the filing is for 2017 Q1. Income and cash flow comparisons are against the three months ended June 30, 2016; balance sheet comparisons are against March 31, 2017.
Business context and results
CorVel provides managed-care and medical cost-containment services, primarily to workers’ compensation, auto insurance, and group-health payors. It reports one operating segment. Patient management and network solutions each represented 55.5% and 44.5% of revenue, respectively, in both comparative quarters.
| Metric | Q1 FY2017 | Q1 FY2018 | Change |
|---|---|---|---|
| Revenue | $128.5 million | $137.6 million | +7.1% |
| Gross profit / margin | $25.6 million / 19.9% | $28.8 million / 20.9% | +12.5%; margin +1.0 percentage point |
| General and administrative expense | $13.5 million | $14.6 million | +8.7% |
| Income before tax | $12.1 million | $14.2 million | +16.8% |
| Net income | $7.5 million | $8.8 million | +17.1% |
| Diluted EPS | $0.38 | $0.46 | +21.1% |
| Operating cash flow | $8.1 million | $21.4 million | +$13.2 million |
Financial position and cash flow
- At June 30, cash and cash equivalents were $35.0 million, customer deposits $31.7 million, and total assets $240.5 million. Working capital was $39.0 million, versus $38.8 million at March 31.
- CorVel had no debt outstanding. Its revolving credit facility provides up to $10 million; the company reported covenant compliance and expects to renew the facility, which expires in September 2017. Separately issued letters of credit totaled $4.5 million.
- Quarterly capital expenditures were $5.3 million. Financing cash outflow was $9.7 million, primarily reflecting $11.2 million spent repurchasing shares. Cash increased $6.4 million during the quarter.
- The operating cash flow increase was attributed principally to net income and changes in accrued liabilities and taxes payable, including timing differences in bonus and estimated-tax payments.
- Contractual obligations totaled $61.7 million, including $57.7 million of operating leases, $2.2 million of uncertain tax positions, and $1.7 million of software licenses.
Material changes and unusual items
- Revenue increased in both service lines. Patient management revenue rose 7.1%, driven by TPA services, partly offset by lower case-management revenue from non-TPA customers. Network solutions revenue rose 7.1%; bill volume increased 1% and revenue per bill rose 3.2% to $24.47.
- Cost of revenue rose 5.8%, slower than revenue growth; management cited increased field headcount and salaries, including 135 additional field employees. General and administrative expense increased 8.7%, mainly due to legal, marketing, stock-compensation, and private-equity impairment costs.
- The company recorded an additional $283,000 impairment on its $2.25 million cost-method private-equity investment during the quarter. Stock-based compensation expense increased to $922,000 from $516,000.
- CorVel repurchased 249,245 shares for $11.2 million at an average $44.88 per share. The repurchases reduced diluted weighted-average shares by 3.8% year over year, supporting EPS growth.
Outlook, risks, and contingencies
- No specific revenue or earnings guidance was provided. Management said cash, expected operating cash flow, and the credit facility should fund obligations and planned activities for at least the next 12 months; it also expects to renew the credit line.
- Management noted the long-term decline in U.S. workplace injury rates, which could reduce claims and medical bills available for review. Other cited risks include competition, customer insourcing or contract termination, pricing pressure, labor and benefit costs, regulatory changes, technology and cybersecurity disruptions, and litigation or professional-liability exposure.
- Management stated ordinary-course litigation is not expected to result in a material payment. It reported no material off-balance-sheet arrangements and no indicators of goodwill or long-lived-asset impairment at June 30. Self-insurance reserves and other estimates could differ from actual outcomes.
- The company anticipated no significant effect from adopting the new revenue standard based on its review of standard contracts, but the impact on non-standard contracts was not yet reasonably estimable. The effects of new financial-instrument and lease standards were still under evaluation.
Important facts for investors to verify
- Confirm that the intended reporting period is Q1 FY2018, not the “2016 Q1” stated in the request metadata.
- Track whether TPA-driven patient-management growth continues and whether case-management declines persist.
- Assess how much of operating cash flow reflects sustainable operations versus timing of bonuses, taxes, and other working-capital items.
- Monitor share repurchase pace, cash usage, and the expected September 2017 credit-line renewal.
- Review future impairment charges on the private-equity investment and the effect of revenue-recognition and lease accounting changes.